Potential statin drug interactions in elderly patients: a review

References

• WHO | Proposed working definition of an older person in Africa for the MDS Project. World Health Organization. Cited 2020 Jun 12. https://www.who.int/healthinfo/survey/ageingdefnolder/en/.
   Google Scholar
• WHO | Men, ageing and health: achieving health across the life span. Cited 2020 Jun 12. https://www.who.int/ageing/publications/men/en/
   Google Scholar
• Ayan M, Pothineni NV, Siraj A, et al. Cardiac drug therapy-considerations in the elderly. J Geriatr Cardiol. 2016;13(12):992–997.
   Google Scholar
• Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet. 1997;33(4):302–312.
   Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
   Google Scholar
• Chamberlin KW, Baker WL. Benefit–risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clin Interv Aging. 2015;10:733–740.
   Google Scholar
• Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007–2017.
   Google Scholar
• Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75–83.
   Google Scholar
• Wynne HA, Blagburn J. Drug treatment in an ageing population: practical implications. Maturitas. 2010;66(3):246–250.
   Google Scholar
• Thürmann PA. Pharmacodynamics and pharmacokinetics in older adults. Curr Opin Anaesthesiol. 2020;33(1):109–113.
   Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
   Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387–1395.
   Google Scholar
• Einarson TR, Gutierrez LM, Rudis M. Drug-related hospital admissions. Ann Pharmacother. 1993;27(7–8):832–840.
   Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J. 2004;329(7456):15–19.
   Google Scholar
• Vrdoljak D, Borovac JAN. Medication in the elderly - considerations and therapy prescription guidelines. Acta Med Acad. 2015;44(2):159–168.
   Google Scholar
• Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Curr Med Res Opin. 2011;27(8):1551–1562.
   Google Scholar
• Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–450.
   Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.
   Google Scholar
• McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331–1336.
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. .
   Google Scholar
• Gu Q, Paulose-Ram R, Burt VL, et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: united States, 2003-2012. NCHS Data Brief. 2014;177(177):1–8.
   Google Scholar
• Armitage J, Baigent C, Barnes E, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–415. .
   Google Scholar
• ABIM Foundation. Cholesterol Drugs for People 75 and Older. Published 2017. Cited 2020 Jul 23. https://www.choosingwisely.org/patient-resources/cholesterol-drugs-for-people-75-and-older/.
   Google Scholar
• Bellosta S, Corsini A, Ferri N. Risk factors for SAMS. In: Taylor B, Thompson P, editors. Statin-Associated Muscle Symptoms. First. Cham, Switzerland: Human Press; 2020. p. 51–61. DOI:10.1007/978-3-030-33304-1_7.
   Google Scholar
• Du Souich P, Roederer G, Dufour R. Myotoxicity of statins: mechanism of action. Pharmacol Ther. 2017;175:1–16. .
   Google Scholar
• Benes LB, Bassi NS, Davidson MH. The risk of hepatotoxicity, new onset diabetes and rhabdomyolysis in the era of high-intensity statin therapy: does statin type matter? Prog Cardiovasc Dis. 2016;59(2):145–152.
   Google Scholar
• FDA. Cholesterol-lowering drugs get labeling changes. Published 2015 Cited 2019 September 14. https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm290856.htm.
   Google Scholar
• Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933–946.
   Google Scholar
• Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: expert position paper of the European society of cardiology working group on thrombosis. Eur Heart J. 2015;36(46):3238–3249.
   Google Scholar
• Leya M, Stone NJ. Statin prescribing in the elderly: special considerations. Curr Atheroscler Rep. 2017;19:11. .
   Google Scholar
• Waring RH, Harris RM, Mitchell SC. Drug metabolism in the elderly: A multifactorial problem? Maturitas. 2017;100:27–32.
   Google Scholar
• Bai JPF, Burckart GJ, Mulberg AE. Literature review of gastrointestinal physiology in the elderly, in pediatric patients, and in patients with gastrointestinal diseases. J Pharm Sci. 2016;105(2):476–483.
   Google Scholar
• Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115–121.
   Google Scholar
• Tan JL, Eastment JG, Poudel A, et al. Age-related changes in hepatic function: an update on implications for drug therapy. Drugs Aging. 2015;32(12):999–1008.
   Google Scholar
• KW WOODHOUSE, MUTCH E, FM WILLIAMS, et al. The effect of age on pathways of drug metabolism in human liver. Age Ageing. 1984;13(6):328–334.
   Google Scholar
• Wiggins BS, Lamprecht DG, Page RL, et al. Recommendations for managing drug–drug interactions with statins and HIV medications. Am J Cardiovasc Drugs. 2017;17(5):375–389.
   Google Scholar
• Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413–428.
   Google Scholar
• Venturini CD, Engroff P, Ely LS, et al. Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. Clin (Sao Paulo). 2011;66(11):1867–1872. http://www.ncbi.nlm.nih.gov/pubmed/22086515
   Google Scholar
• Santos TRA, Silveira EA, Pereira LV, et al. Potential drug-drug interactions in older adults: A population-based study. Geriatr Gerontol Int. 2017;17(12):2336–2346.
   Google Scholar
• Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364–377.
   Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23Suppl 1):III50–7.
   Google Scholar
• Corsini A, Bellosta S. Drug-drug interaction with statins. Expert Rev Clin Pharmacol. 2008;1(1):105–113.
   Google Scholar
• Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2017. DOI:10.1080/14740338.2018.1394455
   Google Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Invest Drugs. 2010;11(3):323–332.
   Google Scholar
• Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(8A):27C–31C.
   Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–1690.
   Google Scholar
• Poirier A, Cascais AC, Bader U, et al. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo. Drug Metab Dispos. 2014;42(9):1411–1422.
   Google Scholar
• Fujino H, Saito T, Ogawa S, et al. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005;57(10):1305–1311.
   Google Scholar
• Shirasaka Y, Suzuki K, Shichiri M, et al. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet. 2011;26(2):171–179.
   Google Scholar
• Knauer MJ, Urquhart BL, Meyer ZU, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010;106(2):297–306.
   Google Scholar
• Mandery K, Bujok K, Schmidt I, et al. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010;80(11):1746–1753.
   Google Scholar
• Koenen A, Köck K, Keiser M, et al. Steroid hormones specifically modify the activity of organic anion transporting polypeptides. Eur J Pharm Sci. 2012;47(4):774–780.
   Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5(7):703–729.
   Google Scholar
• Schirris TJJ, Ritschel T, Bilos A, et al. Statin lactonization by Uridine 5′-Diphospho-glucuronosyltransferases (UGTs). Mol Pharm. 2015;12(11):4048–4055.
   Google Scholar
• Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyl transferase enzymes involved in lactonization. Xenobiotica. 2003;33(1):27–41.
   Google Scholar
• FDA. Guidance for industry drug interaction studies. study design, data analysis, implications for dosing, and labeling recommendations. Published 2012. Cited 2020 Jun 23. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm
   Google Scholar
• FDA. Clinical drug interaction studies — cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry.; 2020. Cited 2020 August 22. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions.
   Google Scholar
• FDA. Drug development and drug interactions. Published 2018 Cited 2020 Aug 25. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions.
   Google Scholar
• Egger SS, Ratz Bravo AE, Hess L, et al. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 2007;24(5):429–440.
   Google Scholar
• Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67(5):507–519.
   Google Scholar
• Gallo P, De Vincentis A, Pedone C, et al. Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019;65:51–57.
   Google Scholar
• Therapeutics E. NEXLETOL Highlights of prescribing information. Cited August 23, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf
   Google Scholar
• Corsini A, Bellosta S, Davidson MHH. Pharmacokinetic interactions between statins and fibrates. discussion 34K-35K Am J Cardiol. 2005;969A:44K–49K.
   Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. November 2018. Cited 2019 Feb 5. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625.
   Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   Google Scholar
• Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   Google Scholar
• Novartis. Entresto. Summary of product characteristics. 2015.
   Google Scholar
• EMA. European Medicines Agency. Sacubitril/valsartan approval. EMEA/H/C/004062. Published 2015 Cited 2020 August 22. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004062/human_med_001929.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Lin W, Ji T, Einolf H, et al. Evaluation of drug-drug interaction potential between sacubitril/valsartan (LCZ696) and statins using a physiologically based pharmacokinetic model. J Pharm Sci. 2017;106(5):1439–1451.
   Google Scholar
• Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American heart association. Circulation. 2016;134(21):e468–e495.
   Google Scholar
• Antoniou T, Macdonald EM, Yao Z, et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ. 2017;189(1):E4–E10.
   Google Scholar
• Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33(4):537–546.
   Google Scholar
• Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018;135:60–79.
   Google Scholar
• AstraZeneca. Ticagrelor [package insert]. 2014.
   Google Scholar
• Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(3):477–487.
   Google Scholar
• Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73(15):1681–1709.
   Google Scholar
• Banakh I, Haji K, Kung R, et al. Severe rhabdomyolysis due to presumed drug interactions between atorvastatin with amlodipine and ticagrelor. Case Rep Crit Care. 2017;2017:3801819.
   Google Scholar
• Kido K, Wheeler MB, Seratnahaei A, et al. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc. 2015;55(3):320–323.
   Google Scholar
• Theetha Kariyanna P, Haseeb S, Singh Chowdhury Y, et al. Ticagrelor and statin interaction induces rhabdomyolysis and acute renal failure: case reports and scoping review. Am J Med Case Reports. 2019;7(12):337–341.
   Google Scholar
• Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor leads to statin-induced rhabdomyolysis: A case report. Am J Case Rep. 2017;18:1238–1241.
   Google Scholar
• Siepmann T, Heinke D, Kepplinger J, et al. Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - A randomized, double-blind, double-dummy crossover study. Br J Clin Pharmacol. 2014;78(5):1058–1066.
   Google Scholar
• Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45(4):422–433.
   Google Scholar
• Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225–1228.
   Google Scholar
• La Fave S The impact of COVID-19 on older adults. Published 2020. Cited 2020 Jun 11. https://hub.jhu.edu/2020/05/05/impact-of-covid-19-on-the-elderly/
   Google Scholar
• Provenzani A, Polidori P. Covid-19 and drug therapy, what we learned. Int J Clin Pharm. 2020;42:3.
   Google Scholar
• Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020. DOI:10.1111/joim.13091.
   Google Scholar
• Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.
   Google Scholar
• European Medicines Agency. First COVID-19 treatment recommended for EU authorisation. Published 2020. Cited 2020 Jun 25. https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation
   Google Scholar
• Yang K. What do we know about remdesivir drug interactions? Clin Transl Sci. May 2020. DOI:10.1111/cts.12815.
   Google Scholar
• FDA. Drug Development and Drug interactions: table of substrates, inhibitors and inducers. Cited 2020 Aug 23. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table4-2.
   Google Scholar
• Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21SUPPL). DOI:10.1161/01.cir.0000129505.34151.23
   Google Scholar
• Dashti-Khavidaki S, Khalili H. Considerations for statin therapy in patients with COVID-19. Iran J Kidney Dis. 2020;14(4):247–255. DOI:10.1002/phar.2397
   Google Scholar
• De Spiegeleer A, Bronselaer A, Teo JT, et al. The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents. medRxiv. 2020;2020.05.11.20096347. May. doi:10.1101/2020.05.11.20096347
   Google Scholar
• Abdel-latif RG, Mohammed S, Elgendy IY. Statin therapy and SAR-COV-2: an available and potential therapy? Eur Heart J Cardiovasc Pharmacother. May 2020. DOI:10.1093/ehjcvp/pvaa050.
   Google Scholar
• Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM An Int J Med. Mar 2020. DOI:10.1093/qjmed/hcaa103.
   Google Scholar
• University of Liverpool. Liverpool Drug Interactions Group University of Liverpool. COVID-19 drug interactions. Cited 2020 Aug 19. https://www.covid19-druginteractions.org. Published 2020.
   Google Scholar
• Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV. Pharmacotherapy. 2000;20(9I):1066–1071.
   Google Scholar
• University of Liverpool. Drug Interaction Checker Lite. Published 2020. Cited 2020 Aug 19. https://www.hiv-druginteractions.org/drug_queries/new.
   Google Scholar
• Godinho R, Bugnon S, Gracin T, et al. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report. BMC Nephrol. 2019;20:1.
   Google Scholar
• Hare CB, Vu MP, Grunfeld C, et al. Simvastatin‐Nelfinavir Interaction Implicated in Rhabdomyolysis and Death. Clin Infect Dis. 2002;35(10):e111–e112.
   Google Scholar
• Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45(12):3445–3450.
   Google Scholar
• Schmidt GA, Hoehns JD, Purcell JL, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20(4):411–416.
   Google Scholar
• Liverpool COVID-19 Interactions. Published 2020 Cited 2020 Jun 11. https://www.covid19-druginteractions.org/.
   Google Scholar
• Burgess MJ, Zeuli JD, Kasten MJ. Management of HIV/AIDS in older patients–drug/drug interactions and adherence to antiretroviral therapy. HIV/AIDS - Res Palliat Care. 2015;7:251–264.
   Google Scholar
• Courlet P, Decosterd LA, Alves Saldanha S, et al. Influence of drug–drug interactions on the pharmacokinetics of atorvastatin and its major active metabolite ortho-OH-atorvastatin in aging people living with HIV. Clin Pharmacokinet. 2020. DOI:10.1007/s40262-020-00876-0.
   Google Scholar
• Ferri N, Bellosta S, Baldessin L, et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592–599.
   Google Scholar
• Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687–1693.
   Google Scholar
• Dickmann LJ, Patel SK, Rock DA, et al. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011;39(8):1415–1422.
   Google Scholar
• Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int. 2012;32(9):2601–2604.
   Google Scholar
• Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229(1):174–181.
   Google Scholar
• Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81–89.
   Google Scholar
• Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–740.
   Google Scholar
• Lee EB, Daskalakis N, Xu C, et al. Disease–drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2017;56(6):607–615.
   Google Scholar
• Arrigoni E, Del Re M, Fidilio L, et al. Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins. Int J Mol Sci. 2017;18(1):104–111.
   Google Scholar
• Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics. 2005;15(6):415–421.
   Google Scholar
• Hou Q, Li S, Li L, et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Med. 2015;94(37):e1268.
   Google Scholar
• Oshiro C, Mangravite L, Klein T, et al. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010;20(3):211–216.
   Google Scholar
• DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400–408.
   Google Scholar
• Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87(1):130–133.
   Google Scholar
• Lee H-K, Hu M, Lui SS, et al. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013;14(11):1283–1294.
   Google Scholar
• Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics. 2012;13(7):757–762.
   Google Scholar
• Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–2590.
   Google Scholar
• Rodrigues MCS, De Oliveira C. Interações medicamentosas e reações adversas a medicamentos em polifarmácia em idosos: uma revisão integrativa. Rev Lat Am Enfermagem. 2016;24. DOI:10.1590/1518-8345.1316.2800.
   Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Hear J. 2015;36(17):1012–1022.
   Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83–94.
   Google Scholar
• Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pr. 2005;17(4):123–132. .
   Google Scholar
• Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can J Cardiol. 2016;32(7):S35–S65.
   Google Scholar
• Reeve E, Thompson W, Deprescribing: FB. A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11.
   Google Scholar
• Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700.
   Google Scholar
• Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol. 2019;73(20):2584–2595. .
   Google Scholar
• Eilat-Tsanani S, Mor E, Schonmann Y. Statin use over 65 years of age and all-cause mortality: a 10-year follow-up of 19 518 people. J Am Geriatr Soc. 2019;67(10):2038–2044.
   Google Scholar
• Motter FR, Fritzen JS, Hilmer SN, et al. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;74(6):679–700.
   Google Scholar
• Gujjarlamudi H. Polytherapy and drug interactions in elderly. J Midlife Health. 2016;7(3):105–107.
   Google Scholar
• Verdoia M, Galasso G, Filardi PP, et al. Statins and elderly: from clinical trials to daily practice. Curr Vasc Pharmacol. 2018;17(3):233–238.
   Google Scholar